Everolimus [EVE6]

The treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression where all the following criteria are met:

  1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
  2. The patient has histopathologically proven well differentiated neuroendocrine tumour of pancreatic origin
  3. The patient has unresectable or metastatic disease
  4. The patient has exhibited disease progression in past 12 months
  5. The patient has a performance status of 0-1
  6. The patient has had no previous treatment with a mTOR inhibitor.
  7. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).* *Requests for continuation after treatment breaks over this duration of treatment unplanned should be made via the treatment break approval process will 8. Everolimus otherwise be used as set out in its Summary of Product Characteristics (SPC).

[NHS funded]{.badge .rounded-pill .bg-success} From: 26 September 2017

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: TA449 (13 May 2017)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.